Becker's Healthcare September 26, 2024
Alexandra Murphy

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20.

Here are five things to know:

  1. KarXT is a coformulation of xanomeline and trospium chloride, designed to selectively activate muscarinic receptors in the brain, unlike traditional antipsychotics that primarily target dopamine receptors.
  2. The safety and effectiveness of the drug was assessed in phase 3 trials, which showed KarXT had a 9.6 point reduction in positive and negative syndrome scale scores compared to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article